Autres langues Bristol-Myers Squibb Company Lima

Actions

BMYUS

US1101221083

Produits pharmaceutiques

Temps réel estimé Cboe BZX 01:06:17 17/09/2026			Varia. 5j.	Varia. 1 janv.
63,60 ^USD	-4,83%		0,00%	+24,06%

16/09	Novo Nordisk collabore avec Anthropic pour accélérer la découverte et le développement de médicaments	MT
16/09	Le secteur pharmaceutique mise sur l'IA pour réduire ses coûts et ses délais	RE

Autres langues

16/09	Novo Nordisk to Collaborate With Anthropic to Help Accelerate Drug Discovery, Development
16/09	Analystenempfehlungen: BMW, Elmos Semiconductor, Schindler, Stellantis, Apple, Chipotle…
16/09	Pharma sector doubles down on AI to slash costs, timelines
16/09	Wall Street vor der Zinsabrechnung
16/09	Afternoon Meeting: La hora de la verdad de los tipos de interés
16/09	Wall Street's Rate Reckoning
16/09	Bristol-Myers Squibb Company Declares Quarterly Dividend, Payable on November 2, 2026
16/09	Bristol-Myers Squibb Keeps Quarterly Dividend at $0.63 a Share, Payable Nov. 2 to Shareholders of Record on Oct. 2
16/09	Bristol Myers Squibb Announces Dividend
16/09	Analyst recommendations: Stellantis, Apple, BofA, Chevron, Chipotle…
10/09	Bristol Myers Squibb Insider Sold Shares Worth $403,498, According to a Recent SEC Filing
10/09	Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says
10/09	Aktien Schweiz schlagen sich wacker in ungünstigem Marktumfeld
10/09	Importante accionista de Novartis pide cambios en directorio tras reveses en ensayos clínicos
10/09	Novartis-Grossaktionär fordert nach Rückschlägen Veränderungen im Verwaltungsrat
10/09	Major Novartis shareholder calls for board shake-up after drug trial setbacks
08/09	Bristol Myers Squibb Announces Positive Phase 2 Results from Registrational QUINTESSENTIAL Trial of Arlocabtagene Autoleucel in Adult Patients with Quadruple-Class Exposed Relapsed and Refractory Multiple Myeloma
08/09	Bristol Myers Squibb's Phase 2 Study of Arlocabtagene Autoleucel Meets Key Endpoints
08/09	Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
08/09	Bristol Myers Squibb's therapy meets mid-stage trial goal
08/09	Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
04/09	Bristol Myers Squibb Paused Zola-Cel Trials Over Safety Concerns
03/09	Rural Pharmacies Identify Thousands of Patients at Risk of Stroke, Heart Disease, Pilot Program Finds
01/09	Novartis: interrompe studi clinici dopo decessi di pazienti
01/09	Promising results for Bristol Myers in cardiomyopathy